AU3956195A - Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same - Google Patents

Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Info

Publication number
AU3956195A
AU3956195A AU39561/95A AU3956195A AU3956195A AU 3956195 A AU3956195 A AU 3956195A AU 39561/95 A AU39561/95 A AU 39561/95A AU 3956195 A AU3956195 A AU 3956195A AU 3956195 A AU3956195 A AU 3956195A
Authority
AU
Australia
Prior art keywords
vaccines
methods
same
enteric bacteria
producing enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU39561/95A
Other versions
AU704283B2 (en
Inventor
Steven M Frey
John L Pace
Richard I Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Microcarb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/538,545 external-priority patent/US5679564A/en
Application filed by Microcarb Inc filed Critical Microcarb Inc
Publication of AU3956195A publication Critical patent/AU3956195A/en
Application granted granted Critical
Publication of AU704283B2 publication Critical patent/AU704283B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/045—Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU39561/95A 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same Ceased AU704283B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31840994A 1994-10-05 1994-10-05
US318409 1994-10-05
US08/538,545 US5679564A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US08/538545 1995-10-03
US08/538,543 US5681736A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US08/538543 1995-10-03
PCT/US1995/013196 WO1996011258A1 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Publications (2)

Publication Number Publication Date
AU3956195A true AU3956195A (en) 1996-05-02
AU704283B2 AU704283B2 (en) 1999-04-15

Family

ID=27405987

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39561/95A Ceased AU704283B2 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Country Status (16)

Country Link
EP (1) EP0804542A4 (en)
JP (1) JP3394047B2 (en)
CN (1) CN1168693A (en)
AU (1) AU704283B2 (en)
BR (1) BR9509276A (en)
CA (1) CA2202027A1 (en)
CZ (1) CZ104397A3 (en)
FI (1) FI971403A (en)
HU (1) HUT77876A (en)
IL (1) IL115521A0 (en)
MX (1) MX9702431A (en)
NO (1) NO971519L (en)
NZ (1) NZ295907A (en)
PL (1) PL182700B1 (en)
SG (2) SG73510A1 (en)
WO (1) WO1996011258A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ295877A (en) * 1994-10-05 1999-03-29 Antex Biolog Inc A vaccine comprising the helicobacter bacterium and its use
EP2327720A1 (en) * 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
WO2007108903A2 (en) * 2006-03-17 2007-09-27 Cerebus Biologicals, Inc. Campylobacter vaccines and methods of use
WO2008146830A1 (en) * 2007-05-28 2008-12-04 The Kitasato Institute Bordetella parapertussis-containing whole-cell vaccine composition
CN107513553B (en) * 2017-09-18 2021-05-18 江南大学 Method for screening lactobacillus with antagonistic campylobacter jejuni infection function
CN109633151B (en) * 2018-12-26 2022-03-11 西北农林科技大学 Salmonella enteritidis detection method, test strip and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt

Also Published As

Publication number Publication date
FI971403A0 (en) 1997-04-04
PL319580A1 (en) 1997-08-18
NO971519D0 (en) 1997-04-03
BR9509276A (en) 1997-11-18
EP0804542A4 (en) 1998-10-28
HUT77876A (en) 1998-09-28
CZ104397A3 (en) 1998-06-17
AU704283B2 (en) 1999-04-15
NO971519L (en) 1997-05-27
JPH10507347A (en) 1998-07-21
IL115521A0 (en) 1996-06-18
SG73510A1 (en) 2000-06-20
WO1996011258A1 (en) 1996-04-18
NZ295907A (en) 1999-04-29
CN1168693A (en) 1997-12-24
MX9702431A (en) 1998-05-31
JP3394047B2 (en) 2003-04-07
EP0804542A1 (en) 1997-11-05
FI971403A (en) 1997-06-04
SG73509A1 (en) 2000-06-20
PL182700B1 (en) 2002-02-28
CA2202027A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
EP0555366A4 (en) Bacterial attenuation method and vaccine
EP0769963A4 (en) Polyepitope vaccines
HU9602310D0 (en) Urease-based vaccine and treatment for helicobacter infection
GB9513261D0 (en) Vaccines
AU2158995A (en) Compositions and methods for vaccines comprising alpha-galactosyl epitopes
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
GB9410922D0 (en) Vaccines
AU4114893A (en) Method for producing a bacterial vaccine and novel vaccines produced thereby
AU2981395A (en) Method of identifying and producing antigen peptides and use thereof as vaccines
PL324975A1 (en) Antigenic preparations
AU3956195A (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
AU4450696A (en) Enhanced immunogenic vaccine
AU1538895A (en) Anti-allergic vaccine
IL122587A (en) Mycoplasma synoviae a vaccine comprising same and methods for preparation of the vaccine
AU5091898A (en) Method of vaccinating infants against infections
AU2971692A (en) Flystrike antigen and vaccine and method for preparation
GB9503867D0 (en) Vaccines and diagnostics
AU715243C (en) Acellular antibordetella vaccine
GB9416667D0 (en) Vaccines and diagnostics
AU773000C (en) Polyepitope vaccines
GB9406708D0 (en) Vaccines
GB9320317D0 (en) Vaccines and diagnostics
AUPM707994A0 (en) Polyepitope vaccines
ZA964016B (en) Bacterial antigens and vaccine compositions
AU8497298A (en) Improved vaccines and method therefor